Animal studies show that transitory biomarkers for potential effects are seen for the brain, blood, liver, and eyes. Neurologic effects , including behavioral and neurophysiological changes, have been observed in chronic human and animal inhalation studies. Occupational and animal studies also show blood pressure elevation, elevated serum cholesterol, vascular atherosclerotic effects, and altered liver metabolizing capability from chronic exposure to carbon disulfide. Animal studies support these findings . Developmental effects, including birth defects, embryotoxicity, and functional and behavioral disturbances, have been observed in animal studies.
Pharmacokinetic studies show that carbon disulfide reaches the target organs of the fetus.
EPA has classified carbon disulfide as a Group D, not classifiable as to human carcinogenicity , due to a lack of adequate data. Exceedance of the RfD does not imply that an adverse health effect would necessarily occur. As the amount and frequency of exposures exceeding the RfD increase, the probability of adverse health effects also increases. The main route of exposure to this compound is in the workplace. Workers in plants that use carbon disulfide in their manufacturing processes have a high degree of exposure potential.